Gm4788 Inhibitors
Gm4788 inhibitors are a class of chemical compounds specifically designed to target and inhibit the function of the Gm4788 gene, which, like many other genes with limited characterization, is thought to play a role in various regulatory and cellular processes. Gm4788 is part of a family of genes that are often involved in maintaining cellular homeostasis, signaling, and gene expression regulation. Though the precise biological functions of Gm4788 have not been fully elucidated, it is likely involved in modulating transcriptional activity or interacting with cellular proteins that influence important pathways such as cell growth, differentiation, and response to stress. By inhibiting Gm4788, researchers can block these interactions, allowing them to explore the gene's specific roles in cellular dynamics and its broader impact on regulatory networks within the cell.
In research settings, Gm4788 inhibitors are valuable tools for investigating the molecular mechanisms that Gm4788 might regulate. By blocking its activity, scientists can study the downstream effects of Gm4788 inhibition on cellular processes like gene expression, intracellular signaling, and protein interactions. This inhibition provides insights into how Gm4788 contributes to regulating key pathways that govern cell behavior, including how the gene interacts with other proteins or factors that influence cellular responses. Additionally, Gm4788 inhibitors help researchers understand the broader regulatory networks that control critical processes such as cell proliferation, differentiation, or adaptation to environmental conditions. Through these studies, the use of Gm4788 inhibitors enhances our understanding of the functional role of lesser-known genes in maintaining cellular integrity, offering deeper insights into the complex molecular systems that ensure proper cellular function and regulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Sirolimus, an mTOR inhibitor, disrupts complement activation indirectly by inhibiting intracellular signaling pathways. Its interference with the PI3K/AKT/mTOR pathway indirectly regulates Cfhr4 expression and influences complement activation. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib, a Bruton's tyrosine kinase inhibitor, hampers complement regulation by impacting B-cell receptor signaling. The modulation of this pathway indirectly influences Cfhr4, contributing to altered complement activation dynamics. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus, an mTOR inhibitor, intervenes in complement activation pathways. By suppressing mTOR signaling, it indirectly affects Cfhr4 expression, leading to altered complement component C3b binding and heparin binding activities. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor, disrupts the PI3K/AKT pathway, indirectly influencing Cfhr4 function. This interference modulates complement activation by altering the regulatory dynamics of Cfhr4 in the extracellular space. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a p38 MAPK inhibitor, impacts the MAPK signaling pathway. By inhibiting this pathway, it indirectly influences Cfhr4, altering its complement regulatory functions. The disruption of MAPK signaling contributes to modified complement activation. | ||||||
JNK Inhibitor VIII | 894804-07-0 | sc-202673 | 5 mg | $272.00 | 2 | |
JNK Inhibitor VIII interferes with the JNK signaling pathway, indirectly affecting Cfhr4 function. Its impact on intracellular signaling pathways contributes to the modulation of complement activation by influencing Cfhr4-mediated complement component interactions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, modulates intracellular signaling cascades. By disrupting the PI3K/AKT pathway, it indirectly influences Cfhr4, altering complement activation dynamics. The modulation of this pathway contributes to changes in Cfhr4-mediated regulatory functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, disrupts JNK signaling pathways. Its impact on intracellular signaling indirectly influences Cfhr4, contributing to altered complement activation dynamics. The modulation of JNK signaling leads to changes in Cfhr4-mediated regulatory functions. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an AKT kinase inhibitor, modulates the PI3K/AKT pathway. Its impact on intracellular signaling cascades indirectly influences Cfhr4, leading to altered complement activation dynamics and regulatory processes. The disruption of this pathway contributes to changes in Cfhr4 function. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK inhibitor, modulates the JAK/STAT signaling pathway. Its impact on intracellular signaling cascades indirectly influences Cfhr4, leading to altered complement activation dynamics and regulatory processes. The disruption of JAK/STAT signaling contributes to changes in Cfhr4 function. | ||||||